All patients
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
anti-inflammatoty and immuno-therapy in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results ConPlas-19, 2020 0.56 [0.20; 1.57]
DAWN-Plasma, 2021 0.61 [0.24; 1.55]
Hegerova, 2020 0.26 [0.05; 1.49]
NCT04397757, 2021 0.47 [0.04; 5.45]
Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
0.71 [0.37 ; 1.38 ] ConPlas-19, 2020, DAWN-Plasma, 2021, Hegerova, 2020, NCT04397757, 2021, Sekine (PLACOVID), 2021 5 26% 1,112 moderate not evaluable death D28detailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
Amra, 2021 0.47 [0.12; 1.93]
ASCOT, 2021 0.60 [0.06; 5.99]
Balcells, 2020 4.22 [0.33; 53.77]
Bennett-Guerrero, 2021 0.86 [0.24; 3.11]
Bihariesingh-Sanchit (SuriCovid), 2021 0.39 [0.13; 1.19]
Brunetti, 2020 0.20 [0.05; 0.80]
CAN-COVID, 2020 0.67 [0.30; 1.50]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.12 [0.86; 1.46]
ConPlas-19, 2020 0.49 [0.20; 1.19]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-ANA-1, 2021 0.91 [0.38; 2.19]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
Davoudi-Monfared, 2020 0.30 [0.11; 0.83]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
Gharebaghi, 2020 0.00 [0.00; 0.09]
GLUCOCOVID, 2020 0.63 [0.25; 1.60]
Horby, 2021 1.01 [0.93; 1.10]
ITAC, 2022 0.80 [0.42; 1.52]
Jamaati, 2021 1.19 [0.38; 3.72]
Joyner, 2020 1.18 [0.99; 1.41]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Karampitsakos, 2021 0.30 [0.11; 0.83]
Kirenga, 2021 1.25 [0.46; 3.39]
Lanzoni, 2021 0.14 [0.02; 0.96]
Li, 2020 0.59 [0.22; 1.59]
LIFESAVER, 2021 2.00 [0.16; 24.66]
MARIPOSA, 2021 1.43 [0.42; 4.87]
Menichetti, 2021 0.75 [0.37; 1.53]
Metcovid, 2020 0.92 [0.67; 1.28]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PICP19 (Ray), 2020 0.67 [0.30; 1.51]
PLACID, 2020 1.04 [0.66; 1.63]
PLACO-COVID, 2021 1.71 [0.72; 4.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
Rashad, 2021 2.86 [1.36; 6.01]
Rashad, 2021 0.35 [0.17; 0.74]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
REMAP-CAP, fixed 7-day course, 2020 1.03 [0.54; 1.98]
REMAP-CAP, shock-dependent course, 2020 1.10 [0.58; 2.10]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.59 [0.33; 1.06]
Sakoulas, 2020 0.29 [0.03; 3.13]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.56 [0.34; 7.13]
Tang X, 2020 0.98 [0.93; 1.02]
TOCOVID, 0 0.99 [0.02; 50.02]
Veiga, 2021 2.70 [0.92; 7.92]
0.88 [0.82 ; 0.94 ] ACTT-2 (Kalil), 2020, AlQahtani, 2020, Aman, 2021, Amra, 2021, ASCOT, 2021, Balcells, 2020, Bennett-Guerrero, 2021, Bihariesingh-Sanchit (SuriCovid), 2021, Brunetti, 2020, CAN-COVID, 2020, Co-CLARITY, 2021, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Davoudi-Monfared, 2020, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Gharebaghi, 2020, GLUCOCOVID, 2020, Horby, 2021, ITAC, 2022, Jamaati, 2021, Joyner, 2020, Kalil (ACTT-3), 2021, Karampitsakos, 2021, Kirenga, 2021, Lanzoni, 2021, Li, 2020, LIFESAVER, 2021, MARIPOSA, 2021, Menichetti, 2021, Metcovid, 2020, NCT04377750 (HMO-0224-20), 0, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04528368, 2021, NCT04577534 (COVIDSTORM), 0, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PICP19 (Ray), 2020, PLACID, 2020, PLACO-COVID, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Raman, 2021, Rashad, 2021, Rashad, 2021, RECOVER, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Tabarsi, 2020, Talaschian, 2021, Tang X, 2020, TOCOVID, 0, Veiga, 2021 87 41% 66,224 moderate critical death or transfer to ICUdetailed results Ana-COVID (Huet), 2020 0.22 [0.10; 0.49]
BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
COLCHIVID, 2021 0.83 [0.35; 1.95]
GLUCOCOVID, 2020 0.68 [0.37; 1.25]
HNF Hospital Tocilizumab multidisciplinary team, 2020 0.13 [0.03; 0.49]
Lopardo, 2021 0.65 [0.35; 1.22]
PLACID, 2020 1.07 [0.73; 1.57]
Tziolos, 2021 0.93 [0.87; 0.99]
0.69 [0.49 ; 0.96 ] Ana-COVID (Huet), 2020, BACC Bay Tocilizumab Trial, 2020, COLCHIVID, 2021, GLUCOCOVID, 2020, HNF Hospital Tocilizumab multidisciplinary team, 2020, Lopardo, 2021, PLACID, 2020, Tziolos, 2021 8 70% 1,520 moderate serious deathsdetailed results Abolghasemi, 2020 0.54 [0.26; 1.13]
ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Albani, 2020 1.15 [0.91; 1.46]
AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
Andrew, 2020 0.76 [0.57; 1.01]
ARI-RAF (Della-Torre), 2020 0.36 [0.08; 1.65]
ASCOT, 2021 0.60 [0.06; 5.99]
BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
Balcells, 2020 3.26 [0.62; 17.12]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
Bihariesingh-Sanchit (SuriCovid), 2021 0.22 [0.23; 0.21]
Biran, 2020 0.64 [0.47; 0.87]
Bruce, 2020 0.89 [0.52; 1.53]
Brunetti, 2020 0.20 [0.05; 0.80]
CAN-COVID, 2020 0.67 [0.30; 1.50]
Cantini, 2020 0.06 [0.00; 1.21]
Cao, 2020 0.15 [0.01; 3.29]
CAPE-COVID, 2020 0.45 [0.20; 1.02]
Capra, 2020 0.04 [0.00; 0.33]
CAPSID, 2021 0.84 [0.28; 2.50]
CCAP-2, 2021 2.03 [0.61; 6.77]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
Colaneri, 2020 0.78 [0.06; 9.73]
COLCHIVID, 2021 0.69 [0.20; 2.40]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59]
CONFIDENT, 2020 0.84 [0.52; 1.37]
ConPlas-19, 2020 0.46 [0.19; 1.15]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COP-COVID-19, 2021 0.96 [0.36; 2.56]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-ANA-1, 2021 0.97 [0.46; 2.04]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
CPC-SARS, 2021 0.04 [0.01; 0.26]
Darazam, 2021 1.21 [0.65; 2.25]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
DEVENT, 0 0.47 [0.22; 1.00]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Drake, 2021 0.95 [0.84; 1.07]
Duan, 2020 0.12 [0.01; 2.86]
Edalatifard, 2020 0.29 [0.15; 0.56]
EMPACTA, 2020 1.13 [0.54; 2.40]
Esquivel-Moynelo, 2020 1.10 [0.02; 57.31]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
Fernández Cruz, 2020 0.34 [0.12; 0.98]
Fu, 2020 1.00 [0.02; 51.66]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
Gharebaghi, 2020 0.00 [0.00; 0.09]
GLUCOCOVID, 2020 0.63 [0.25; 1.60]
GRECCO-19, 2020 0.21 [0.02; 1.97]
Guan, 2020 0.67 [0.22; 2.09]
Hamed, 2021 1.83 [0.16; 21.66]
Hegerova, 2020 0.26 [0.05; 1.49]
HNF Hospital Tocilizumab multidisciplinary team, 2020 0.36 [0.10; 1.30]
Holm K, 2021 0.49 [0.08; 2.89]
Horby, 2021 1.01 [0.93; 1.10]
ILBS-COVID-02 (Bajpai M), 2020 3.82 [0.35; 41.96]
Ip, 2020 0.76 [0.57; 1.01]
Ip, 2020 0.76 [0.57; 1.01]
ITAC, 2022 0.80 [0.42; 1.52]
Jamaati, 2021 1.19 [0.38; 3.72]
Jianfeng, 2020 2.83 [1.72; 4.65]
Joyner, 2020 1.18 [0.99; 1.41]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Kirenga, 2021 1.25 [0.46; 3.39]
Kumar, 2021 0.06 [0.00; 1.35]
LACCPT, 2021 1.17 [0.58; 2.36]
Lanzoni, 2021 0.11 [0.01; 0.93]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
Li, 2020 0.59 [0.22; 1.59]
Li, 2021 1.04 [0.02; 53.73]
Libster, 2020 0.50 [0.09; 2.71]
LIFESAVER, 2021 2.00 [0.16; 24.66]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
Lopardo, 2021 0.57 [0.24; 1.37]
Lopes MIF, 2020 1.06 [0.02; 56.61]
Lu, 2020 3.28 [0.99; 10.90]
Majmundar, 2020 0.53 [0.22; 1.29]
Malgorzata, 2020 0.41 [0.19; 0.89]
Martinez-Sanz, 2020 0.34 [0.16; 0.72]
Mathilde, 2020 0.25 [0.06; 1.09]
Menichetti, 2021 0.75 [0.37; 1.53]
Metcovid, 2020 0.92 [0.67; 1.28]
Monreal, 2020 2.46 [1.58; 3.83]
Murugesan, 2022 1.00 [0.02; 51.41]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
NCT04385199, 2021 0.75 [0.15; 3.77]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04442191, 2021 0.11 [0.00; 143.68]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PICP19 (Ray), 2020 0.67 [0.30; 1.51]
PLACID, 2020 1.04 [0.66; 1.63]
PLACO-COVID, 2021 1.71 [0.72; 4.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raef, 2020 0.45 [0.22; 0.92]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
Ranjbar, 2021 0.40 [0.15; 1.08]
Rashad, 2021 2.16 [1.14; 4.09]
Rashad, 2021 0.46 [0.24; 0.88]
Rasheed, 2020 0.13 [0.01; 1.09]
RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2021 0.85 [0.76; 0.95]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
REMAP-CAP sarilumab, 2021 0.51 [0.25; 1.07]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Rodriguez-Bano (CS pulse dose), 2020 0.64 [0.31; 1.33]
Rodriguez-Bano (intermediate-high dose CS), 2020 1.21 [0.62; 2.36]
Rojas-Marte, 2020 0.62 [0.35; 1.09]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rossotti, 2020 0.50 [0.26; 0.95]
Rutgers, 2021 0.62 [0.36; 1.07]
Sakoulas, 2020 0.29 [0.03; 3.13]
Salehzadeh, 2020 1.00 [0.02; 51.41]
Salton (Methylprednisolone), 2020 0.29 [0.12; 0.72]
SAM-COVID-19, 2020 0.07 [0.02; 0.20]
Sandhu, 2020 0.36 [0.19; 0.69]
sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80]
sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Scarsi, 2020 0.15 [0.06; 0.37]
Sean, 2020 0.46 [0.17; 1.25]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55]
SOLIDARITY (interferon), 2020 1.16 [0.96; 1.40]
Somers, 2020 0.55 [0.33; 0.91]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
SPRINTER, 2022 0.79 [0.38; 1.66]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.25 [0.30; 5.14]
Tang X, 2020 0.98 [0.93; 1.02]
TOCI-RAF Study Group (Campochiaro), 2020 0.37 [0.11; 1.23]
TOCOVID, 0 0.99 [0.02; 50.02]
Tsai, 2020 1.00 [0.46; 2.15]
Tziolos, 2021 0.47 [0.28; 0.80]
Veiga, 2021 2.70 [0.92; 7.92]
Wang, 2020 1.58 [0.13; 18.81]
Wang, 2020 1.00 [0.02; 52.54]
Wang (early IFN), 2020 0.10 [0.02; 0.50]
Wu, 2020 0.38 [0.20; 0.72]
Zhou, 2020 3.18 [1.63; 6.19]
0.72 [0.64 ; 0.81 ] Abolghasemi, 2020, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, Albani, 2020, AlQahtani, 2020, Aman, 2021, Andrew, 2020, ARI-RAF (Della-Torre), 2020, ASCOT, 2021, BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, Bihariesingh-Sanchit (SuriCovid), 2021, Biran, 2020, Bruce, 2020, Brunetti, 2020, CAN-COVID, 2020, Cantini, 2020, Cao, 2020, CAPE-COVID, 2020, Capra, 2020, CAPSID, 2021, CCAP-2, 2021, Co-CLARITY, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, Colaneri, 2020, COLCHIVID, 2021, COLCOVID, 2021, CONCOR-1, 2021, ConCOVID (Gharbharan et al.), 2020, CONFIDENT, 2020, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COP-COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, CP-COVID-19, 2021, CPC-SARS, 2021, Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, DEVENT, 0, DEXA-COVID19, 2020, Drake, 2021, Duan, 2020, Edalatifard, 2020, EMPACTA, 2020, Esquivel-Moynelo, 2020, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, Fernández Cruz, 2020, Fu, 2020, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Gharebaghi, 2020, GLUCOCOVID, 2020, GRECCO-19, 2020, Guan, 2020, Hamed, 2021, Hegerova, 2020, HNF Hospital Tocilizumab multidisciplinary team, 2020, Holm K, 2021, Horby, 2021, ILBS-COVID-02 (Bajpai M), 2020, Ip, 2020, Ip, 2020, ITAC, 2022, Jamaati, 2021, Jianfeng, 2020, Joyner, 2020, Kalil (ACTT-3), 2021, Kirenga, 2021, Kumar, 2021, LACCPT, 2021, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, Li, 2021, Libster, 2020, LIFESAVER, 2021, LIVE-AIR (Temesgen), 2021, Lopardo, 2021, Lopes MIF, 2020, Lu, 2020, Majmundar, 2020, Malgorzata, 2020, Martinez-Sanz, 2020, Mathilde, 2020, Menichetti, 2021, Metcovid, 2020, Monreal, 2020, Murugesan, 2022, NCT04377750 (HMO-0224-20), 0, NCT04385199, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04442191, 2021, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04528368, 2021, NCT04577534 (COVIDSTORM), 0, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PICP19 (Ray), 2020, PLACID, 2020, PLACO-COVID, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Raef, 2020, Rahmani, 2020, Raman, 2021, Ranjbar, 2021, Rashad, 2021, Rashad, 2021, Rasheed, 2020, RCT-TCZ-COVID-19, 2021, RECOVER, 2021, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rodriguez-Bano (CS pulse dose), 2020, Rodriguez-Bano (intermediate-high dose CS), 2020, Rojas-Marte, 2020, Rosas (REMDACTA), 2021, Rossotti, 2020, Rutgers, 2021, Sakoulas, 2020, Salehzadeh, 2020, Salton (Methylprednisolone), 2020, SAM-COVID-19, 2020, Sandhu, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, SAVE-MORE, 2021, Scarsi, 2020, Sean, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, SOLIDARITY (interferon), 2020, Somers, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, SPRINTER, 2022, Steroids-SARI, 2020, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tabarsi, 2020, Talaschian, 2021, Tang X, 2020, TOCI-RAF Study Group (Campochiaro), 2020, TOCOVID, 0, Tsai, 2020, Tziolos, 2021, Veiga, 2021, Wang, 2020, Wang, 2020, Wang (early IFN), 2020, Wu, 2020, Zhou, 2020 187 94% 111,022 moderate critical deaths (time to event analysis only)detailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Andrew, 2020 0.76 [0.57; 1.01]
ARI-RAF (Della-Torre), 2020 0.36 [0.08; 1.65]
Balcells, 2020 3.26 [0.62; 17.12]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
Bihariesingh-Sanchit (SuriCovid), 2021 0.22 [0.23; 0.21]
Bruce, 2020 0.89 [0.52; 1.53]
Capra, 2020 0.04 [0.00; 0.33]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConPlas-19, 2020 0.46 [0.19; 1.15]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Edalatifard, 2020 0.29 [0.15; 0.56]
Ip, 2020 0.76 [0.57; 1.01]
Jianfeng, 2020 3.02 [1.59; 5.73]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lanzoni, 2021 0.11 [0.01; 0.93]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
PlasmAr, 2020 0.93 [0.47; 1.85]
Rashad, 2021 0.46 [0.24; 0.88]
Rashad, 2021 2.16 [1.14; 4.09]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
Salton (Methylprednisolone), 2020 0.29 [0.12; 0.72]
Scarsi, 2020 0.15 [0.06; 0.37]
Somers, 2020 0.55 [0.33; 0.91]
Talaschian, 2021 1.25 [0.30; 5.14]
0.72 [0.52 ; 0.99 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTT-2 (Kalil), 2020, Andrew, 2020, ARI-RAF (Della-Torre), 2020, Balcells, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, Bihariesingh-Sanchit (SuriCovid), 2021, Bruce, 2020, Capra, 2020, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, COV-BARRIER, 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Davoudi-Monfared, 2020, DAWN-Plasma, 2021, Edalatifard, 2020, Ip, 2020, Jianfeng, 2020, Kalil (ACTT-3), 2021, Lanzoni, 2021, LIVE-AIR (Temesgen), 2021, PlasmAr, 2020, Rashad, 2021, Rashad, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, Salton (Methylprednisolone), 2020, Scarsi, 2020, Somers, 2020, Talaschian, 2021 36 95% 13,973 moderate critical clinical deteriorationdetailed results Ana-COVID (Huet), 2020 0.22 [0.10; 0.49]
BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
Balcells, 2020 1.46 [0.44; 4.81]
Cao, 2020 0.11 [0.01; 2.21]
CAPSID, 2021 0.63 [0.29; 1.40]
CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58]
ConPlas-19, 2020 1.00 [0.65; 1.53]
CONTAIN COVID-19, 2021 0.94 [0.75; 1.18]
CORIMUNO-ANA-1, 2021 0.89 [0.42; 1.92]
CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
COV-BARRIER, 2021 1.12 [0.58; 2.16]
EMPACTA, 2020 0.55 [0.33; 0.92]
Esquivel-Moynelo, 2020 2.29 [0.20; 26.58]
GRECCO-19, 2020 0.11 [0.01; 1.08]
Jeong, 2020 1.65 [1.21; 2.24]
Kirenga, 2021 0.91 [0.38; 2.17]
Li, 2021 0.52 [0.02; 15.78]
Libster, 2020 0.52 [0.29; 0.94]
PLACID, 2020 1.04 [0.54; 1.99]
Ravichandran, 2021 0.02 [0.00; 0.36]
RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86]
Salton (Methylprednisolone), 2020 0.41 [0.24; 0.71]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
Shu, 2020 0.27 [0.01; 5.58]
Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77]
SPRINTER, 2022 0.69 [0.43; 1.11]
STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
Tang X, 2020 1.00 [0.13; 7.45]
Wang, 2020 1.00 [0.02; 52.54]
Wenxin, 2020 0.08 [0.01; 0.62]
Yan et al., 2020 7.56 [1.17; 48.89]
0.70 [0.56 ; 0.87 ] Ana-COVID (Huet), 2020, BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, Cao, 2020, CAPSID, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, COV-BARRIER, 2021, EMPACTA, 2020, Esquivel-Moynelo, 2020, GRECCO-19, 2020, Jeong, 2020, Kirenga, 2021, Li, 2021, Libster, 2020, PLACID, 2020, Ravichandran, 2021, RCT-TCZ-COVID-19, 2021, Salton (Methylprednisolone), 2020, SAVE-MORE, 2021, Shu, 2020, Soin AS (COVINTOC), 2021, SPRINTER, 2022, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020, Wang, 2020, Wenxin, 2020, Yan et al., 2020 34 67% 8,286 moderate critical clinical improvementdetailed results ACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20]
ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
Balcells, 2020 0.91 [0.52; 1.60]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
CAN-COVID, 2020 1.39 [0.76; 2.54]
Cao, 2020 1.67 [0.84; 3.33]
CAPSID, 2021 1.58 [0.71; 3.49]
ConPlas-19, 2020 0.95 [0.60; 1.52]
COV-BARRIER, 2021 1.25 [1.04; 1.50]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Darazam, 2021 1.37 [0.88; 2.13]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
Dongsheng Wang, 2020 2.37 [0.40; 13.96]
Edalatifard, 2020 12.00 [2.39; 60.20]
EMPACTA, 2020 1.15 [0.90; 1.47]
ITAC, 2022 1.06 [0.77; 1.45]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Li, 2020 1.40 [0.79; 2.49]
Li, 2021 1.76 [1.10; 2.81]
Lopardo, 2021 1.61 [0.75; 3.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
REMAP-CAP sarilumab, 2021 1.76 [1.12; 2.78]
REMAP-CAP, fixed 7-day course, 2020 1.43 [0.91; 2.26]
REMAP-CAP, shock-dependent course, 2020 1.22 [0.76; 1.95]
sarilumab phase 2 high dose, 0 2.09 [1.00; 4.36]
sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
Tang X, 2020 1.04 [0.67; 1.62]
Wenxin, 2020 12.75 [1.61; 100.79]
1.22 [1.12 ; 1.33 ] ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, Bennett-Guerrero, 2021, CAN-COVID, 2020, Cao, 2020, CAPSID, 2021, ConPlas-19, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Davoudi-Monfared, 2020, Dongsheng Wang, 2020, Edalatifard, 2020, EMPACTA, 2020, ITAC, 2022, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Li, 2020, Li, 2021, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020, Tang X, 2020, Wenxin, 2020 42 44% 11,759 moderate critical clinical improvement (14-day)detailed results ACTT-2 (Kalil), 2020 1.30 [1.03; 1.64]
Cao, 2020 2.00 [0.58; 6.94]
COV-BARRIER, 2021 1.28 [1.05; 1.56]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
Li, 2020 2.27 [0.90; 5.72]
Li, 2021 2.86 [1.24; 6.62]
Pandit, 2021 8.77 [0.94; 81.67]
REMAP-CAP sarilumab, 2021 1.86 [1.20; 2.87]
REMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03]
REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
Tang X, 2020 1.33 [0.57; 3.11]
1.37 [1.15 ; 1.64 ] ACTT-2 (Kalil), 2020, Cao, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, Kalil (ACTT-3), 2021, Li, 2020, Li, 2021, Pandit, 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Shashi Bhushan, 2021, Shu, 2020, Tang X, 2020 14 40% 5,222 moderate critical clinical improvement (21-day)detailed results Cao, 2020 1.50 [0.22; 10.08]
1.50 [0.22 ; 10.08 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (28-day)detailed results Bennett-Guerrero, 2021 1.02 [0.25; 4.20]
Brunetti, 2020 3.50 [1.19; 10.29]
COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Li, 2020 1.42 [0.65; 3.10]
Li, 2021 4.26 [1.10; 16.44]
O’Donnell, 2021 1.38 [0.73; 2.61]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 3.68 [0.18; 75.54]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 3.15 [1.39; 7.14]
1.70 [1.22 ; 2.38 ] Bennett-Guerrero, 2021, Brunetti, 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Li, 2020, Li, 2021, O’Donnell, 2021, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020 13 52% 1,486 moderate critical clinical improvement (7-day)detailed results ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
Cao, 2020 2.38 [0.38; 14.70]
ITAC, 2022 1.06 [0.77; 1.45]
Li, 2020 0.98 [0.27; 3.58]
Li, 2021 1.83 [0.41; 8.14]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
Shu, 2020 6.72 [1.50; 30.07]
Tsiakos, 2020 2.36 [1.10; 5.09]
1.46 [0.99 ; 2.14 ] ACTIV-3/TICO LY-CoV555 , 2020, Cao, 2020, ITAC, 2022, Li, 2020, Li, 2021, Shashi Bhushan, 2021, Shu, 2020, Tsiakos, 2020 8 51% 1,580 moderate serious clinical improvement (time to event analysis only)detailed results ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
Balcells, 2020 0.91 [0.52; 1.60]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
Cao, 2020 1.67 [0.84; 3.33]
ConPlas-19, 2020 0.95 [0.60; 1.52]
Darazam, 2021 1.37 [0.88; 2.13]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
EMPACTA, 2020 1.15 [0.90; 1.47]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
Li, 2020 1.40 [0.79; 2.49]
Li, 2021 1.76 [1.10; 2.81]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
Rahmani, 2020 3.41 [1.33; 8.73]
sarimulab phase 2 low dose, 0 0.96 [0.53; 1.73]
SPRINTER, 2022 1.02 [0.81; 1.28]
Tang X, 2020 1.04 [0.67; 1.62]
1.12 [1.03 ; 1.21 ] ACTT-2 (Kalil), 2020, Balcells, 2020, Bennett-Guerrero, 2021, Cao, 2020, ConPlas-19, 2020, Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, EMPACTA, 2020, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, Li, 2021, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, sarimulab phase 2 low dose, 0, SPRINTER, 2022, Tang X, 2020 21 11% 4,870 moderate critical death or ventilationdetailed results ACTT-2 (Kalil), 2020 0.69 [0.50; 0.95]
BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
Balcells, 2020 0.67 [0.14; 3.26]
CAPE-COVID, 2020 0.71 [0.37; 1.35]
COLCOVID, 2021 0.83 [0.67; 1.02]
CONCOR-1, 2021 1.16 [0.94; 1.43]
ConPlas-19, 2020 0.94 [0.86; 1.02]
CORIMUNO-ANA-1, 2021 0.97 [0.62; 1.52]
CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
DAWN-Plasma, 2021 1.01 [0.64; 1.59]
EMPACTA, 2020 0.56 [0.32; 0.97]
LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
Menichetti, 2021 0.88 [0.59; 1.32]
NCT04310228-FAVI (Zhao), 2020 3.60 [0.13; 102.66]
RECOVERY, 2021 0.85 [0.78; 0.93]
RECOVERY, 2022 0.90 [0.81; 0.99]
RECOVERY (colchicine), 2021 1.02 [0.96; 1.09]
RECOVERY (plasma), 2021 0.99 [0.93; 1.05]
RECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92]
RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01]
REMAP-CAP, fixed 7-day course, 2020 2.74 [1.16; 6.46]
REMAP-CAP, shock-dependent course, 2020 1.24 [0.55; 2.78]
Rodriguez-Bano (CS pulse dose), 2020 0.61 [0.43; 0.86]
Rodriguez-Bano (intermediate-high dose CS), 2020 1.00 [0.71; 1.40]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
Rutgers, 2021 0.65 [0.43; 0.99]
SAM-COVID-19, 2020 0.32 [0.22; 0.47]
sarilumab phase 2 high dose, 0 0.39 [0.18; 0.82]
sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44]
SOLIDARITY (interferon), 2020 1.05 [0.90; 1.23]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
SPRINTER, 2022 0.85 [0.45; 1.61]
STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97]
Synairgen SG016, 2020 0.38 [0.09; 1.63]
Veiga, 2021 1.54 [0.65; 3.63]
0.86 [0.81 ; 0.92 ] ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, CAPE-COVID, 2020, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, DAWN-Plasma, 2021, EMPACTA, 2020, LIVE-AIR (Temesgen), 2021, Menichetti, 2021, NCT04310228-FAVI (Zhao), 2020, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rodriguez-Bano (CS pulse dose), 2020, Rodriguez-Bano (intermediate-high dose CS), 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, SAM-COVID-19, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, SOLIDARITY (interferon), 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, SPRINTER, 2022, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Veiga, 2021 36 66% 55,837 moderate critical hospital dischargedetailed results ACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20]
Brunetti, 2020 5.00 [1.25; 20.04]
Cantini, 2020 23.94 [10.77; 53.20]
CAPE-COVID, 2020 1.67 [0.87; 3.19]
COLCHIVID, 2021 1.13 [0.76; 1.67]
ConPlas-19, 2020 1.02 [0.82; 1.28]
Davoudi-Monfared, 2020 1.96 [0.76; 5.03]
DAWN-Plasma, 2021 1.06 [0.87; 1.30]
EMPACTA, 2020 1.16 [0.90; 1.49]
Majmundar, 2020 3.65 [2.20; 6.06]
MARIPOSA, 2021 0.88 [0.55; 1.40]
Rahmani, 2020 3.44 [0.64; 18.49]
RECOVERY (colchicine), 2021 0.98 [0.94; 1.03]
RECOVERY (plasma), 2021 0.99 [0.92; 1.07]
RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31]
RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
Sandhu, 2020 2.80 [1.46; 5.37]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
SPRINTER, 2022 1.06 [0.89; 1.27]
Synairgen SG016, 2020 1.63 [0.61; 4.35]
1.22 [1.10 ; 1.36 ] ACTIV-3/TICO LY-CoV555 , 2020, Brunetti, 2020, Cantini, 2020, CAPE-COVID, 2020, COLCHIVID, 2021, ConPlas-19, 2020, Davoudi-Monfared, 2020, DAWN-Plasma, 2021, EMPACTA, 2020, Majmundar, 2020, MARIPOSA, 2021, Rahmani, 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, Rosas (REMDACTA), 2021, Sandhu, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, SPRINTER, 2022, Synairgen SG016, 2020 21 84% 37,274 moderate critical hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable mechanical ventilationdetailed results ACTT-2 (Kalil), 2020 0.64 [0.44; 0.93]
AlQahtani, 2020 0.67 [0.22; 2.02]
Balcells, 2020 2.98 [0.41; 21.61]
CAPE-COVID, 2020 0.95 [0.44; 2.04]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COPLA-II trial, 2020 0.58 [0.37; 0.92]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Davoudi-Monfared, 2020 0.72 [0.29; 1.76]
Drake, 2021 0.96 [0.79; 1.16]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.85 [0.68; 1.06]
GRECCO-19, 2020 0.17 [0.02; 1.48]
Hamed, 2021 3.15 [0.57; 17.48]
Holm K, 2021 0.39 [0.01; 12.68]
Jamaati, 2021 1.38 [0.45; 4.20]
Li, 2021 0.52 [0.02; 15.78]
Li (Methylprednisolone, Shanghai cohort), 2020 0.24 [0.07; 0.87]
Majmundar, 2020 0.31 [0.14; 0.69]
MARIPOSA, 2021 0.88 [0.37; 2.10]
Metcovid, 2020 1.19 [0.56; 2.49]
NCT04397757, 2021 0.41 [0.13; 1.35]
O’Donnell, 2021 1.50 [0.47; 4.82]
PLACID, 2020 0.99 [0.54; 1.81]
PlasmAr, 2020 0.86 [0.39; 1.93]
Rahmani, 2020 0.29 [0.05; 1.56]
Ranjbar, 2021 0.36 [0.13; 0.97]
RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69]
RECOVERY, 2022 0.87 [0.74; 1.02]
RECOVERY (colchicine), 2021 1.04 [0.93; 1.16]
RECOVERY (plasma), 2021 0.98 [0.88; 1.09]
RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95]
Rutgers, 2021 0.65 [0.35; 1.24]
Sakoulas, 2020 0.19 [0.03; 1.11]
Salton (Methylprednisolone), 2020 0.50 [0.24; 1.04]
Sandhu, 2020 0.40 [0.21; 0.77]
sarilumab phase 2 high dose, 0 0.27 [0.10; 0.71]
sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
Shu, 2020 0.59 [0.02; 14.04]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38]
Tabarsi, 2020 1.49 [0.59; 3.78]
0.78 [0.70 ; 0.88 ] ACTT-2 (Kalil), 2020, AlQahtani, 2020, Balcells, 2020, CAPE-COVID, 2020, COL-COVID (Pascual-Figal), 2021, COPLA-II trial, 2020, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Drake, 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, Hamed, 2021, Holm K, 2021, Jamaati, 2021, Li, 2021, Li (Methylprednisolone, Shanghai cohort), 2020, Majmundar, 2020, MARIPOSA, 2021, Metcovid, 2020, NCT04397757, 2021, O’Donnell, 2021, PLACID, 2020, PlasmAr, 2020, Rahmani, 2020, Ranjbar, 2021, RCT-TCZ-COVID-19, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY dexamethasone, 2020, Rutgers, 2021, Sakoulas, 2020, Salton (Methylprednisolone), 2020, Sandhu, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, SAVE-MORE, 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, Tabarsi, 2020 44 44% 50,122 moderate critical mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
DAWN-Plasma, 2021 1.08 [0.65; 1.80]
0.97 [0.62 ; 1.52 ] CP-COVID-19, 2021, DAWN-Plasma, 2021 2 0% 583 moderate not evaluable radiologic improvement (14-day)detailed results Cai -FAVIPIRAVIR, 2020 6.48 [1.72; 24.44]
Cao, 2020 5.54 [1.01; 30.50]
Jamaati, 2021 4.89 [1.15; 20.79]
NCT04310228-FAVI (Zhao), 2020 0.32 [0.06; 1.63]
Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28]
Tabarsi, 2020 2.33 [0.45; 12.00]
2.82 [1.35 ; 5.89 ] Cai -FAVIPIRAVIR, 2020, Cao, 2020, Jamaati, 2021, NCT04310228-FAVI (Zhao), 2020, Rashad (CLARI vs SoC), 2021, Tabarsi, 2020 6 48% 453 moderate not evaluable Recovery (time to event analysis only)detailed results SPRINTER, 2022 1.02 [0.81; 1.28]
1.02 [0.81 ; 1.28 ] SPRINTER, 2022 1 0% 623 NA not evaluable viral clearance detailed results Balcells, 2020 2.66 [0.69; 10.20]
CP-COVID-19, 2021 1.12 [0.16; 7.84]
Esquivel-Moynelo, 2020 3.26 [1.53; 6.95]
Jagannathan, 2020 0.81 [0.56; 1.18]
Li, 2021 7.68 [0.91; 65.15]
Pandit, 2021 2.33 [0.55; 9.83]
Raman, 2021 36.42 [10.85; 122.18]
Ravichandran, 2021 1.71 [0.80; 3.64]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
Tang X, 2020 1.78 [1.06; 3.00]
2.60 [1.42 ; 4.73 ] Balcells, 2020, CP-COVID-19, 2021, Esquivel-Moynelo, 2020, Jagannathan, 2020, Li, 2021, Pandit, 2021, Raman, 2021, Ravichandran, 2021, Salman, 2020, Shashi Bhushan, 2021, Tang X, 2020 11 79% 1,043 moderate critical viral clearance (time to event analysis only)detailed results Esquivel-Moynelo, 2020 3.26 [1.53; 6.95]
Jagannathan, 2020 0.81 [0.56; 1.18]
Li, 2021 1.74 [1.10; 2.75]
Tang X, 2020 1.78 [1.06; 3.00]
1.60 [0.92 ; 2.79 ] Esquivel-Moynelo, 2020, Jagannathan, 2020, Li, 2021, Tang X, 2020 4 79% 365 moderate not evaluable viral clearance by day 14detailed results CP-COVID-19, 2021 1.51 [0.33; 6.94]
Esquivel-Moynelo, 2020 5.90 [0.28; 122.94]
Kirenga, 2021 0.95 [0.76; 1.19]
Li, 2021 1.74 [0.71; 4.29]
Pandit, 2021 10.23 [1.12; 93.35]
Raman, 2021 36.42 [10.85; 122.18]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
1.38 [0.20 ; 9.41 ] CP-COVID-19, 2021, Esquivel-Moynelo, 2020, Kirenga, 2021, Li, 2021, Pandit, 2021, Raman, 2021, Shashi Bhushan, 2021 7 96% 1,841 moderate not evaluable viral clearance by day 7detailed results Balcells, 2020 2.66 [0.69; 10.20]
Esquivel-Moynelo, 2020 3.09 [1.04; 9.17]
Kirenga, 2021 0.87 [0.65; 1.16]
Li, 2021 2.20 [0.95; 5.10]
Pandit, 2021 2.33 [0.55; 9.83]
PLACID, 2020 1.20 [1.00; 1.44]
Ravichandran, 2021 1.71 [0.80; 3.64]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.57 [1.13 ; 2.18 ] Balcells, 2020, Esquivel-Moynelo, 2020, Kirenga, 2021, Li, 2021, Pandit, 2021, PLACID, 2020, Ravichandran, 2021, Salman, 2020, Shashi Bhushan, 2021 9 58% 1,107 moderate serious ICU admissiondetailed results Albani, 2020 0.48 [0.34; 0.67]
Cantini, 2020 0.04 [0.01; 0.32]
COL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69]
Colaneri, 2020 0.11 [0.00; Infinity]
COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Drake, 2021 1.01 [0.87; 1.17]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.99 [0.56; 1.75]
GLUCOCOVID, 2020 0.85 [0.27; 2.67]
Hamed, 2021 3.15 [0.57; 17.48]
HNF Hospital Tocilizumab multidisciplinary team, 2020 0.03 [0.00; 0.60]
Libster, 2020 0.33 [0.07; 1.58]
Lopardo, 2021 0.67 [0.35; 1.28]
Lopes MIF, 2020 1.06 [0.06; 18.45]
Majmundar, 2020 0.16 [0.07; 0.35]
Rahmani, 2020 0.37 [0.14; 1.00]
Rutgers, 2021 0.96 [0.55; 1.68]
Salton (Methylprednisolone), 2020 0.51 [0.25; 1.06]
Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64]
Tabarsi, 2020 0.56 [0.18; 1.74]
Tang X, 2020 1.00 [0.13; 7.45]
Tziolos, 2021 0.19 [0.10; 0.39]
0.57 [0.42 ; 0.77 ] Albani, 2020, Cantini, 2020, COL-COVID (Pascual-Figal), 2021, Colaneri, 2020, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Drake, 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GLUCOCOVID, 2020, Hamed, 2021, HNF Hospital Tocilizumab multidisciplinary team, 2020, Libster, 2020, Lopardo, 2021, Lopes MIF, 2020, Majmundar, 2020, Rahmani, 2020, Rutgers, 2021, Salton (Methylprednisolone), 2020, Soin AS (COVINTOC), 2021, Tabarsi, 2020, Tang X, 2020, Tziolos, 2021 24 70% 12,815 moderate critical off oxygenationdetailed results Davoudi-Monfared, 2020 8.57 [1.43; 51.36]
ILBS-COVID-02 (Bajpai M), 2020 0.26 [0.02; 2.88]
sarilumab phase 2 high dose, 0 1.99 [0.95; 4.15]
sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21]
1.62 [0.67 ; 3.92 ] Davoudi-Monfared, 2020, ILBS-COVID-02 (Bajpai M), 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 4 58% 331 serious not evaluable recoverydetailed results ACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32]
ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37]
ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46]
COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
Lanzoni, 2021 3.46 [1.05; 11.35]
Synairgen SG016, 2020 2.19 [1.03; 4.67]
Talaschian, 2021 0.64 [0.14; 2.92]
1.17 [0.98 ; 1.39 ] ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020, COV-BARRIER (critically ill), 2022, Lanzoni, 2021, Synairgen SG016, 2020, Talaschian, 2021 7 25% 1,290 low not evaluable composite safety outcome detailed results ACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11]
1.56 [0.78 ; 3.11 ] ACTIV-3/TICO LY-CoV555 , 2020 1 0% 314 NA not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable related SAE (TRSAE)detailed results Wang, 2020 2.04 [0.07; 63.93]
2.04 [0.07 ; 63.93 ] Wang, 2020 1 0% 48 NA not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
Balcells, 2020 4.54 [0.20; 105.23]
CAN-COVID, 2020 0.73 [0.45; 1.19]
Cao, 2020 0.11 [0.01; 2.21]
CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
CONCOR-1, 2021 1.27 [1.02; 1.58]
ConPlas-19, 2020 0.89 [0.43; 1.86]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Dongsheng Wang, 2020 0.91 [0.02; 47.31]
Edalatifard, 2020 0.81 [0.11; 6.17]
ITAC, 2022 0.98 [0.66; 1.46]
Jagannathan, 2020 1.00 [0.14; 7.34]
Lanzoni, 2021 0.10 [0.01; 0.69]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
O’Donnell, 2021 0.64 [0.35; 1.17]
Pandit, 2021 0.95 [0.02; 50.33]
PlasmAr, 2020 1.40 [0.78; 2.51]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
REMAP-CAP, fixed 7-day course, 2020 3.01 [0.33; 27.32]
REMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
Shi, 2020 1.08 [0.04; 32.96]
Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
1.04 [0.90 ; 1.20 ] BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, CAN-COVID, 2020, Cao, 2020, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, CONCOR-1, 2021, ConPlas-19, 2020, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Edalatifard, 2020, ITAC, 2022, Jagannathan, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, O’Donnell, 2021, Pandit, 2021, PlasmAr, 2020, Raman, 2021, REMAP-CAP (plasma), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 2021 29 19% 8,651 moderate low superinfectiondetailed results ACTT-2 (Kalil), 2020 0.50 [0.32; 0.79]
CAPE-COVID, 2020 0.81 [0.49; 1.34]
Davoudi-Monfared, 2020 2.41 [0.75; 7.73]
Metcovid, 2020 0.98 [0.65; 1.47]
Rahmani, 2020 0.18 [0.02; 1.59]
Somers, 2020 3.27 [1.66; 6.43]
1.04 [0.57 ; 1.90 ] ACTT-2 (Kalil), 2020, CAPE-COVID, 2020, Davoudi-Monfared, 2020, Metcovid, 2020, Rahmani, 2020, Somers, 2020 6 80% 1,876 moderate not evaluable acute kidney injury detailed results Tziolos, 2021 0.43 [0.14; 1.34]
0.43 [0.14 ; 1.34 ] Tziolos, 2021 1 0% 369 NA not evaluable adverse eventsdetailed results Cai -FAVIPIRAVIR, 2020 0.10 [0.03; 0.34]
Cao, 2020 1.60 [0.38; 6.81]
COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08]
COLCHIVID, 2021 1.63 [0.67; 3.95]
COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Dongsheng Wang, 2020 9.64 [2.76; 33.75]
Esquivel-Moynelo, 2020 1.33 [0.45; 3.92]
Jagannathan, 2020 1.33 [0.63; 2.78]
Kirenga, 2021 1.13 [0.50; 2.58]
Lanzoni, 2021 0.18 [0.02; 1.95]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
NCT04310228-FAVI (Zhao), 2020 0.60 [0.05; 6.80]
Pandit, 2021 1.68 [0.47; 5.97]
Raman, 2021 1.36 [0.56; 3.30]
Ravichandran, 2021 1.04 [0.02; 52.86]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Sakoulas, 2020 1.00 [0.02; 53.46]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Shi, 2020 0.88 [0.38; 2.03]
Shu, 2020 2.48 [0.05; 132.54]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87]
Veiga, 2021 1.65 [0.81; 3.37]
Wang, 2020 3.57 [0.93; 13.72]
1.21 [0.96 ; 1.51 ] Cai -FAVIPIRAVIR, 2020, Cao, 2020, COL-COVID (Pascual-Figal), 2021, COLCHIVID, 2021, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Esquivel-Moynelo, 2020, Jagannathan, 2020, Kirenga, 2021, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, NCT04310228-FAVI (Zhao), 2020, Pandit, 2021, Raman, 2021, Ravichandran, 2021, Rosas (REMDACTA), 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, Veiga, 2021, Wang, 2020 26 42% 3,292 moderate low arrhythmiadetailed results Tziolos, 2021 0.16 [0.03; 0.90]
0.16 [0.03 ; 0.90 ] Tziolos, 2021 1 0% 369 NA not evaluable cardiovascular or renal eventsdetailed results Jeong, 2020 1.87 [1.25; 2.80]
1.87 [1.25 ; 2.80 ] Jeong, 2020 1 0% 1,824 NA not evaluable elevated liver enzymesdetailed results Tziolos, 2021 0.52 [0.18; 1.51]
0.52 [0.18 ; 1.51 ] Tziolos, 2021 1 0% 369 NA not evaluable Myocardial infarction detailed results Tziolos, 2021 0.87 [0.19; 3.92]
0.87 [0.19 ; 3.92 ] Tziolos, 2021 1 0% 369 NA not evaluable venous thromboembolism detailed results Tziolos, 2021 5.23 [0.42; 65.62]
5.23 [0.42 ; 65.62 ] Tziolos, 2021 1 0% 369 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-28 03:01 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525
- roots T: 290